Evrysdi

risdiplam · Roche Registration GmbH
PRIME AUTHORISED IN THE EU

What Evrysdi is used for

Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.

Approved use, as published by the European Medicines Agency.

What the labels mean

  • PRIME: a priority medicine that the EMA supported early because it may meet an unmet need.

Key facts

Brand
Evrysdi
Active substance
risdiplam
Disease area
Muscular Atrophy, Spinal
Medicine group
Other drugs for disorders of the musculo-skeletal system
ATC code
M09AX10
Marketing authorisation holder
Roche Registration GmbH
Authorised in the EU since
2021

Official information

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Evrysdi used for?

Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.

What is the active substance in Evrysdi?

Evrysdi contains risdiplam.

Who makes Evrysdi?

The EU marketing authorisation holder is Roche Registration GmbH.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.